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PCoronary Risk Stratification
The Framingham Predictive
Instrument in Chronic Kidney Disease
Daniel E. Weiner, MD, MS,* Hocine Tighiouart, MS,† Essam F. Elsayed, MD,*
John L. Griffith, PHD,† Deeb N. Salem, MD, FACC,‡ Andrew S. Levey, MD,*
Mark J. Sarnak, MD, MS*
Boston, Massachusetts
Objectives We sought to determine the utility of the Framingham equations in individuals with chronic kidney disease (CKD).
Background The Framingham equations predict incident coronary disease. The utility of these equations is unknown in CKD.
Methods We pooled individuals without pre-existing coronary disease age 45 to 74 years from the ARIC (Atherosclerosis
Risk In Communities) and CHS (Cardiovascular Health Study) trials with CKD, defined by an estimated glomeru-
lar filtration rate of 15 to 60 ml/min/1.73 m2. Using gender-specific models, we determined 5- and 10-year risk
of incident myocardial infarction and fatal coronary disease, and evaluated discriminative and calibration ability
of the Framingham equations for predicting coronary events.
Results There were 577 women and 357 men with CKD. Thirty-five men (9.8%) and 30 women (5.2%) and 74 men
(20.7%) and 56 women (9.7%) had cardiac events within 5 and 10 years, respectively; 5-year events were pre-
dicted in 6.0% and 1.9% and 10-year events in 13.9% and 4.8% of men and women, respectively. For 5-year
events, C-statistics assessing discrimination were 0.62 and 0.77, while 10-year C-statistics were 0.60 and 0.73
for men and women, respectively. Calibration was also poor, with Framingham scores generally underpredicting
events in individuals with CKD at 5 and 10 years. Discrimination was significantly improved by refitting models
with population-specific coefficients, while recalibration improved prediction in women.
Conclusions The Framingham instrument demonstrates poor overall accuracy in predicting cardiac events in individuals with
CKD, although refit models can substantially improve discrimination. Calibration in women can be moderately
improved with adjustment for higher event rates. Development of CKD-specific equations is needed. (J Am Coll
Cardiol 2007;50:217–24) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.03.037(
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She Framingham predictive instrument allows clinicians to
stimate individual patient risk of incident coronary heart
isease by accounting for traditional cardiac risk factors, in-
luding gender, age, blood pressure, cholesterol, diabetes, and
moking (1,2). While the Framingham equation has been
alidated in racially diverse populations including the ARIC
Atherosclerosis Risk In Communities) trial and CHS (Car-
iovascular Health Study), its applicability in individuals with
hronic kidney disease (CKD) is unknown (3).
rom the *Division of Nephrology, †Division of Clinical Care Research, and the
Division of Cardiology, Tufts-New England Medical Center, Boston,
assachusetts. The ARIC study, CHS, and the Framingham Heart and Framing-
am Offspring studies are conducted and supported by the National Heart, Lung, and
lood Institute in collaboration with the individual study investigators. Grant support
as received by Dr. Sarnak (R21 DK068310), Dr. Elsayed (T32 DK007777), and Dr.
einer (K23 DK071636). Amgen Inc., Thousand Oaks, California, provided partial
upport for the creation of the pooled database. The substance of this article was
resented at the 2006 Annual Meeting of the American Society of Nephrology in San
iego, California, November 16, 2006.e
Manuscript received December 12, 2006; revised manuscript received March 9,
007, accepted March 13, 2007.Stage 3 to 4 CKD, defined by a glomerular filtration rate
GFR) between 15 and 60 ml/min/1.73 m2, is extremely
ommon in the U.S., with estimated prevalence of 8 million
dults (4). Chronic kidney disease is an independent risk factor
or cardiovascular disease (CVD), and individuals with CKD
ave a high burden of CVD risk factors and cardiac events
5,6). The mechanism of increased cardiovascular risk in CKD
s uncertain, but is likely secondary to increased severity of
raditional CVD risk factors, most notably hypertension and
iabetes (7). Nontraditional risk factors, including inflamma-
ion, oxidative stress, and anemia, may also contribute (8).
Given the importance of identifying individuals with
KD at highest risk for cardiac events, we evaluated the
tility of the Framingham predictive instrument in a pre-
ominantly stage 3 CKD population.
ethods
tudy design. We utilized 2 limited-access databases that
valuated CVD in community-based populations: ARIC
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ulation-based studies allowed
evaluation of individuals in the
Framingham study age range
while increasing statistical power
and generalizability. From 1987
to 1989, ARIC enrolled 15,792
participants age 45 to 64 years
from 4 communities (9). From
1989 to 1990, CHS enrolled
,201 subjects age 65 years and older in 4 communities; an
dditional 687 African Americans were recruited from 1992
o 1993 (10). To match the Framingham studies (11,12) we
xcluded individuals over 74 years old. Data from the
imited-access database of the 11th examination of Fra-
ingham Heart study cohort and the baseline examination
f the Framingham Offspring study (1971 to 1974) were
sed to reproduce beta-coefficients and survival functions of
he Framingham predictive instrument (11,12).
We quantified kidney function as GFR estimated with
he 4-variable Modification of Diet in Renal Disease study
quation (13–15). We calibrated the ARIC and CHS
aboratories indirectly using NHANES (National Health
nd Nutrition Examination Survey)-III data (16–18). We
efined kidney disease as estimated GFR below 60 ml/min/
.73 m2 (4). Subjects with GFR below 15 ml/min/1.73 m2
ere excluded to avoid individuals likely to require dialysis
n the immediate future.
Baseline characteristics included demographics (age, gen-
er, race); medical history (coronary heart disease, diabetes,
moking); systolic and diastolic blood pressure; and labora-
ory variables (total cholesterol, high-density lipoprotein
holesterol, creatinine). Race was defined as white or Afri-
an American. Cigarette smoking was dichotomized by
urrent use. Diabetes was defined by use of insulin, oral
ypoglycemic medications, or fasting glucose level 140
g/dl (7.8 mmol/l) in order to match the original Framing-
am definition (12). Baseline coronary disease included a
istory of coronary angioplasty, coronary bypass surgery,
nd both recognized and silent myocardial infarction as
efined by consensus committees for the respective studies
9,10).
After exclusions for missing age, race, gender, or creati-
ine data or of nonwhite/non-African American race (n 
02), age over 74 years (n  1,915), and missing baseline
oronary heart disease status (n  317), there were 19,046
ubjects. Of these, 1,106 individuals had estimated GFR
etween 15 and 60 ml/min/1.73 m2. A further 168 with
oronary heart disease, 2 with missing follow-up data, and 2
ith missing blood pressure or laboratory data were ex-
luded, yielding a final population of 934 individuals.
tudy outcome. The primary outcome included myocar-
ial infarction and fatal coronary heart disease. Myocardial
nfarction was defined by both clinically recognized and
Abbreviations
and Acronyms
CKD  chronic kidney
disease
CVD  cardiovascular
disease
GFR  glomerular filtration
rateilent infarctions (noted on screening electrocardiograms). ctatistical analysis. Baseline characteristics for the CKD
ohort were compared with the Framingham derivation
ohort using chi-square and t tests. All p values are 2-sided,
nd, as in Framingham, all analyses are gender-specific.
ISCRIMINATION. Discrimination is the ability of a predic-
ion model to separate those who had events from those
ho did not have events and was quantified by the
-statistic, analogous to the area under a receiver operating
haracteristic curve. We obtained the 10-year Framingham
urvival function from previously published data and repro-
uced the 5-year survival function for myocardial infarction
nd fatal coronary heart disease at the mean values of the
ramingham risk factors by using individual patient data
rom the Framingham (11th visit) and Framingham Off-
pring (baseline visit) datasets, replicating Framingham
echniques (2,12,19). Using these survival functions for
redicting myocardial infarction and fatal coronary heart
isease (defined as “hard” outcomes by Framingham inves-
igators as the more subjective outcome of angina is ex-
luded) and the values for traditional coronary risk factors
blood pressure and lipid categories, age, diabetes, and
moking) from our study population, we utilized coefficients
eveloped by the Framingham investigators to calculate the
ramingham risk score for each individual and further
erive the 5- and 10-year Framingham probability of a
oronary event (2,3,20).
We then created gender-specific “best Cox” models.
hese utilize Cox proportional hazards regression with
ovariates identical to those in the Framingham risk score.
oefficients for these covariates are generated based on the
esults of the predictive model in the CKD population and
ield different coefficients than the original Framingham
odels. For each risk factor, the regression coefficients for the
KD cohort from “best Cox” models and the original Fra-
ingham cohort were compared using a 2-tailed z statistic,
here z  (b[F]  b[C])/SE. The beta coefficients for individ-
al Framingham and CKD covariates are represented by b[F]
nd b[C], respectively, while the standard error (SE) is defined
s (SE[F]
2  SE[C]
2)½. Lastly, we computed 2 gender-
pecific C-statistics: the first applied the Framingham func-
ion to the CKD cohort and the second utilized the “best
ox” model in the CKD cohort. For comparison purposes,
e duplicated this technique in individuals (n  16,689)
rom the pooled cohort with GFR 60 ml/min/1.73 m2
nd no history of coronary artery disease. C-statistics are
ompared using a nonparametric approach (21).
ALIBRATION. Calibration assesses whether predicted out-
omes and actual outcomes agree. Individuals with CKD
ere divided into quintiles of predicted risk based on their
ramingham probabilities, and plots of 5- and 10-year
redicted and actual events adjusted for informative censor-
ng using Kaplan-Meier estimates were created. Differences
etween predicted and actual rates were compared using a
odified Hosmer-Lemeshow chi-square statistic (3). Highhi-square values indicate poor calibration.
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July 17, 2007:217–24 Framingham Prediction in Kidney DiseaseCalibration may be poor in cases where the event rate for
he population being studied is markedly different than in
he Framingham population. In this situation, recalibration
s performed, whereby the event rate of the population being
tudied replaces the event rate of the Framingham popula-
ion, accounting for a systematic difference in event rates
etween the 2 populations (3,20). Importantly, recalibration
oes not affect discrimination. To further account for
ossible differences, we also calculated calibration using the
ender-specific “best Cox” models.
ENSITIVITY ANALYSIS. Because of the high risk of mortal-
ty as a competing outcome in CKD, such that individuals
ith a preponderance of cardiac risk factors may die before
aving a cardiac event, we examined a composite outcome
f cardiac events and all-cause mortality (22). As the
ramingham equations were designed to predict cardiac
vents and not all-cause mortality, these analyses were
erformed using “best Cox” models.
All data were analyzed using SAS Version 9.1 (SAS Insti-
ute, Cary, North Carolina). The Institutional Review Board at
ufts-New England Medical Center approved this project.
Baseline Demographic Characteristics of the CKand Corresponding Baseline Data for the Framin
Table 1 Baseline Demographic Characteristand Corresponding Baseline Data fo
CKD
(n  357)
Age (mean  SD), yrs 65.8  7.6*
History of diabetes (%) 14.6*
Current smoker (%) 15.1*
Blood pressure categories (mm Hg)
Optimal (SBP 120, DBP 80) 25.2†
Normal (SBP 130, DBP 85) 21.8
High normal (SBP 140, DBP 90) 17.4
Stage I (SBP 160, DBP 100) 20.7
Stage II to IV (SBP 60, DBP 100) 14.8
Total cholesterol categories (mg/dl)
160 8.7
160–199 39.2†
200–239 36.4
240–279 11.2†
280 4.5
HDL cholesterol categories (mg/dl)
35 23.8
35–44 36.1
45–49 14.6
50–59 16.2
60 9.2
Kidney function
Creatinine (mg/dl) 1.5  0.3
Estimated GFR (ml/min/1.73 m2) 52.3  7.5
Study of origin (ARIC) 37.0
African American 13.4
All p values 0.05 except: *p  0.001 and †p  0.05 for gender-spe
Framingham subjects. All p values are 2-sided. To convert cholesterol l
by 88.4; to convert glomerular filtration rate (GFR) to ml/s, multiply by 0.016
ARIC Atherosclerosis Risk In Communities study; DBP diastolic blood presults
mong 934 individuals with CKD and no history of
oronary heart disease, 577 (61.7%) were women. Mean
erum creatinine was 1.5 0.3 mg/dl (133 27 mol/l) for
en and 1.2  0.3 mg/dl (106  27 mol/l) for women,
ielding mean estimated GFR of 52.9  7.5 ml/min/1.73
2. There were 131 (14.0%) individuals with diabetes and
17 (66.1%) with hypertension (Table 1). Among men with
KD, there were 35 (9.8%) and 74 (20.7%) cardiac events
ithin 5 and 10 years, respectively. Among women, there
ere 30 (5.2%) and 56 (9.7%) cardiac events, respectively.
dditionally, 53 (14.8%) and 126 (35.3%) men, and 54
9.4%) and 120 (20.8%) women died within 5 and 10 years,
espectively (Table 2).
Beta-coefficients and hazard ratios both for the original
ramingham cohort and for CKD patients based on “best
ox” models are presented in Table 3. Among men,
eta-coefficients significantly differed between Framingham
nd CKD for both hyperlipidemia and the highest blood
ressure group (p  0.05), with the markedly increased risk
ssociated with these characteristics in the Framingham
hortDerivation Population
f the CKD Cohort
Framingham Derivation Population
n Women
Framingham
(n  2,439)
CKD
(n  577)
Framingham
(n  2,812)
48.3 64.0  8.4* 49.6
5.0 13.7* 3.8
40.3 18.2* 37.8
20.2 32.8 34.8
24.3 20.6 21.6
20.2 18.2 15.0
22.5 17.7 18.6
12.8 10.7 10.0
7.5 6.1 7.9
31.3 21.7* 30.3
39.0 38.3† 32.7
16.5 21.3 20.0
5.7 12.7† 9.1
19.2 6.9† 4.3
35.7 19.1† 14.9
15.5 11.6 12.4
19.0 26.7 27.7
10.6 35.7† 40.7
N/A 1.2  0.3 N/A
N/A 53.2  7.5 N/A
N/A 43.2 N/A
0 17.0 0
ferences between individuals with chronic kidney disease (CKD) and
mmol/l, multiply by 0.0259; to convert creatinine to mol/l, multiplyD Cogham
ics o
r the
Me
cific dif
evels to67.
essure; HDL high-density lipoprotein; SBP systolic blood pressure.
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Framingham Prediction in Kidney Disease July 17, 2007:217–24opulation not appreciated in CKD patients. Among
omen with CKD, being in the highest blood pressure
roups was associated with significantly increased risk when
ompared with the Framingham population. Diabetes was
ssociated with a trend toward increased risk in both men
nd women with CKD when compared with the Framing-
am population (p  0.10).
iscrimination. In models using the CKD cohort, discrim-
nation was low in men for both 5- and 10-year probabilities.
Framingham Probabilities and Event Rates for Mand Women in the CKD and Frami gham Deriva
Table 2 Framingham Probabilities and Evenand Women in the CKD and Framin
Me
CKD
(n  357)
Framingham probability (%)
5-yr 6.0  4.6
10-yr 13.9  9.8
Outcomes (%)
5-yr cardiac events 9.8
10-yr cardiac events 20.7
5-yr mortality events 14.8
10-yr mortality events 35.3
Rates were compared using chi-square tests and means using t tests
between individuals with chronic kidney disease (CKD) and Framingham
the derivation cohort for the Framingham equation were not readily av
Framingham derivation cohort using limited access patient level data
Framingham Offspring study.
ox Regression Coefficients for the Cohort of Individuals With CKDnd for the Original Framingham Cohorts for 10-Year Cardiac Outco
Table 3 Cox Regression Coefficients for the Cohort of Individuaand for the Original Framingham Cohorts for 10-Year C
Predictor
Men
CKD (“Best Cox”) FHS
 HR (95% CI)  HR (
Age 0.02 1.02 (0.99–1.06) 0.05 1.05 (1
Age2 — — —
Total cholesterol
160 0.07 0.94 (0.39–2.26) 0.38 0.69 (0
160–199 Reference Ref
200–239 0.01 0.99 (0.58–1.69)* 0.57 1.77 (1
240–279 0.37 0.69 (0.28–1.69)† 0.74 2.10 (1
280 0.17 1.18 (0.41–3.42) 0.83 2.29 (1
HDL cholesterol
35 0.13 0.88 (0.42–1.87)* 0.61 1.84 (1
35–44 0.14 0.87 (0.45–1.68) 0.37 1.45 (0
45–49 Reference Ref
50–59 0.04 0.96 (0.44–2.09) 0.00 1.00 (0
60 0.27 0.76 (0.27–2.19) 0.46 0.63 (0
Blood pressure
Optimal 0.27 1.31 (0.65–2.63) 0.09 1.10 (0
Normal Reference Ref
High normal 0.18 1.19 (0.54–2.64) 0.42 1.53 (0
Stage 1 HTN 0.55 1.74 (0.86–3.51) 0.66 1.93 (1
Stage 2–4 HTN 0.05 0.95 (0.42–2.16)† 0.90 2.45 (1
Diabetes 1.17 3.23 (1.89–5.52)* 0.53 1.69 (1
Smoking 0.32 1.37 (0.75–2.51) 0.73 2.07 (1
p  0.10; †p  0.05. Age is in years, cholesterol levels in mg/dl. To convert cholesterol levels
ramingham cohort.
CI  confidence interval; FHS  Framingham Heart Study; HR  hazard ratio; HTN  hypertension; otodels correctly identified individuals who would develop an
vent 62% and 60% of the time, respectively, in comparison
ith discrimination of 72% and 69% in the non-CKD cohort
ooled from ARIC and CHS and 79% and 73% in the original
ramingham cohort. In men with CKD, “best Cox” models
ignificantly improved discrimination.
In models using the CKD cohort, discrimination in
omen ranged from 77% for 5-year events to 73% for
0-year events; this was similar to that seen in individuals
ohorts
es for Men
Derivation Cohorts
Women
amingham
 2,439)
CKD
(n  577)
Framingham
(n  2,812)
.5  3.6 1.9  2.2 0.9  1.6
.2  7.9 4.8  5.4 2.5  4.0
3.7 5.1 1.4
8.0 9.7 2.8
3.5 9.4 2.3
9.0 20.8 5.8
ting was 2-sided. All p values 0.001 for gender-specific differences
cts. Framingham probabilities and 5- and 10-year mortality data from
in published data; therefore, these were generated by reproducing the
isit 11 of the Framingham Heart study and the baseline visit of the
ith CKD
c Outcomes
Women
CKD (“Best Cox”) FHS
I)  HR (95% CI)  HR (95% CI)
07) 0.01 1.01 (0.54–1.91) 0.17 1.19 (0.97–1.45)
0.00 — 0.001 —
52) 0.26 0.77 (0.21–2.77) 0.21 1.23 (0.27–5.64)
Reference Reference
50) 0.52 0.59 (0.28–1.27)* 0.44 1.55 (0.81–2.96)
10) 0.44 1.55 (0.73–3.32) 0.56 1.74 (0.90–3.40)
76) 0.40 1.50 (0.66–3.42) 0.89 2.44 (1.21–4.93)
88) 0.01 0.99 (0.32–3.11) 0.73 2.08 (1.00–4.31)
21) 0.30 1.35 (0.66–2.78) 0.60 1.82 (1.05–3.16)
0.31 0.74 (0.24–2.26) 0.60 1.82 (1.05–3.14)
60) Reference Reference
18) 0.18 0.84 (0.42–1.68) 0.54 0.58 (0.33–1.02)
82) 0.60 1.82 (0.55–5.97)* 0.74 0.48 (0.22–1.05)
Reference Reference
36) 1.07 2.91 (0.92–9.23)† 0.37 0.69 (0.34–1.42)
92) 1.45 4.26 (1.38–13.16)* 0.22 1.24 (0.69–2.24)
79) 2.24 9.38 (3.09–28.53)† 0.61 1.84 (1.00–3.39)
57) 1.63 5.10 (2.71–9.61)* 0.87 2.38 (1.40–4.06)
68) 0.80 2.23 (1.17–4.27) 0.98 2.65 (1.77–3.97)
l/l multiply by 0.0259. Statistical tests are gender-specific, comparing the CKD cohort with theention C
t Rat
gham
n
Fr
(n
3
8
. All tes
subje
ailablemes
ls W
ardia
95% C
.04–1.
—
.31–1.
erence
.25–2.
.43–3.
.39–3.
.17–2.
.94–2.
erence
.62–1.
.34–1.
.67–1.
erence
.98–2.
.28–2.
.59–3.
.11–2.
.60–2.
to mmoher abbreviations as in Table 1.
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July 17, 2007:217–24 Framingham Prediction in Kidney Diseaseithout CKD. In individuals with CKD, discrimination
mproved with use of “best Cox” models, approaching that
een in the original Framingham cohort (Table 4).
alibration. Among men with CKD, the Framingham
quation consistently underpredicted cardiac events in quintiles
to 4. However, in quintile 5, the Framingham equation
verpredicted cardiac events; notably there was 55% mortality
n this quintile. Overall 5- and 10-year calibration for men was
oor, with chi-square of 33.4 and 71.3, respectively (p 0.001
or both) (Fig. 1). Among women, the Framingham equations
onsistently underpredicted events resulting in poor 5- and
Gender-Specific C-Statistics Demonstrating Discin Individuals With and Without CKD and in the
Table 4 Gender-Specific C-Statistics Demonin Individuals With and Without CKD
Discrimination
CKD
Baseline Best Cox
5-yr 0.62* 0.72
10-yr 0.60* 0.68
W
5-yr 0.77† 0.82
10-yr 0.73‡ 0.81
*p 0.01; †p 0.20; and ‡p 0.001. Comparisons are between C-s
are gender- and duration-of-follow-up-specific.
CKD  chronic kidney disease; FHS  Framingham Heart Study.
Men
non-calibrated: X2=33.4, p<0.01
re-calibrated: X2=13.7, p=0.01
0%
10%
20%
30%
1 2 3 4 5
Quintile of Framingham Risk
5-
Y
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r 
P
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b
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ty
Ob rved Ev ts
Predicted Events  (non-calibrated)
Predicted Events  (re-calibrated)
Men
non-calibrated: X2=71.3, p<0.01
re-calibrated: X2=32.3, p=<0.01
0%
15%
30%
45%
60%
1 2 3 4 5
Quintile of Framingham Risk
10
-Y
ea
r 
P
ro
b
ab
ili
ty
Observed Events
Predicted Events (non-calibrated)
Predicted Events (re-calibrated)
Figure 1 Predicted and Actual 5-Year Risk of Cardiac Events
Graphical presentation of actual 5-year risk of cardiac outcomes in men with
chronic kidney disease along with predicted risk, with and without recalibration
for higher event rates in chronic kidney disease stratified by quintile of pre-
dicted Framingham risk.0-year calibration, with chi-square of 61.2 and 75.1, respec-
ively (p  0.001 for both) (Fig. 2).
Recalibrated models performed somewhat better. Although
rediction remained poor in men (5- and 10-year chi-square of
3.7 (p  0.01) and 32.3 (p  0.001), respectively (Fig. 1),
here was no longer a significant difference in predicted and
bserved events in 5- and 10-year probability models for
omen (Fig. 2). “Best Cox” models performed well for 5- and
0-year probabilities in both men and women, with chi-square
alues of 4.2 and 4.0 for men and 0.8 and 2.5 for women,
espectively (p  0.20 for all).
ation for Framingham Functionsnal FHS De ivation Cohort
ing Discrimination for Framingham Functions
in the Original FHS Derivation Cohort
Non-CKD FHS
Baseline Best Cox Derivation
0.72 0.73 0.79
0.69 0.71 0.73
0.76 0.79 0.83
0.76 0.79 0.76
scores for Framingham Heart study (FHS) and “best Cox” models and
Women
non-calibrated: X2=61.2, p<0.01
re-calibrated: X2=8.7, p=0.07
0%
5%
10%
15%
1 2 3 4 5
Quintile of Framingham Risk
5-
Y
ea
r 
P
ro
b
ab
ili
ty
Ob rved Ev ts
Predicted Events (non-calibrated)
Predicted Events (re-calibrated)
Women
non-calibrated: X2=75.1, p<0.01
re-calibrated: X2=8.9, p=0.06
0%
10%
20%
30%
1 2 3 4 5
Quintile of Framingham Risk
10
-Y
ea
r 
P
ro
b
ab
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ty
Observed Events
Predicted Events (non-calibrated)
Predicted Events (re-calibrated)
Figure 2 Predicted and Actual 10-Year Risk of Cardiac Events
Graphical presentation of actual 10-year risk of cardiac outcomes in women
with chronic kidney disease along with predicted risk, with and without recali-
bration for higher event rates in chronic kidney disease stratified by quintile of
predicted Framingham risk.riminOrigi
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Framingham Prediction in Kidney Disease July 17, 2007:217–24ensitivity analysis. Because individuals with CKD are at
ncreased risk for noncardiovascular mortality and this com-
eting risk may affect cardiac outcomes, we examined calibra-
ion of the Framingham equations for a composite outcome of
yocardial infarction and all-cause mortality. In gender-
pecific 5- and 10-year models, the composite event rate
ncreased as Framingham risk rose (Fig. 3). “Best Cox” models
erformed well for 5- and 10-year probabilities in men, with
hi-square values of 2.1 and 2.3 (p  0.20 for both). In
omen, models also performed relatively well, with chi-square
alues of 2.6 and 7.1, respectively (p  0.10 for both).
iscussion
n the current study, we used a bi-racial, community-based
ohort to assess the utility of the Framingham predictive
quation for cardiac events in individuals with CKD. Our
ndings were as follows: 1) discrimination of the baseline
ramingham equation in individuals with CKD, particu-
arly men, is poor; 2) discrimination can be significantly
mproved with use of “best Cox” models, which utilize the
ame traditional risk factors as the Framingham equation
ut assign different weight to each factor, indicating that
raditional Framingham risk factors are important in CKD
ut that these risk factors carry different influence on cardiac
vents; 3) calibration of the Framingham equation in men
nd women with CKD is poor; and 4) recalibration, which
ccounts for a systematic underestimation of cardiac events
y the Framingham equation in individuals with CKD,
mproves accuracy in women but not in men, and this failure
n men likely is due to the competing outcome of death.
Discrimination is the ability of a prediction model to
eparate those who experience a cardiac event from those
ho do not. The C-statistic expresses the probability of
orrectly identifying from a random pair (containing an
ndividual who will develop and an individual who will not
evelop coronary disease) the individual who will develop
oronary disease (23). In models using the original Fra-
ingham equation, discrimination in men with CKD was
nly 60% to 62%, whereas in men without CKD it was 69%
o 72%, and in the Framingham derivation cohort it was
3% to 79%. Discrimination was better in women but still
ppreciably worse than in the Framingham population. This
s particularly remarkable as individuals comprising the
KD cohort have relatively high GFR (mean 53 ml/min/
.73 m2) and fairly “normal” appearing serum creatinine
evels (mean 1.3 mg/dl). Importantly, this cohort is repre-
entative of the large majority of the 8 million individuals in
he U.S. with CKD. When we assigned different weights to
ach Framingham covariate with “best Cox” models, dis-
rimination improved significantly, approaching that seen in
he non-CKD population and demonstrating that tradi-
ional cardiovascular risk factors are important in individuals
ith CKD but that they differ in magnitude of importance.
Calibration is the measure of how closely predictedutcomes agree with actual outcomes. In models using theriginal Framingham equation, calibration was poor in both
en and women. While the Framingham predictive equa-
ions are an integral component of CVD prevention guide-
ines in the U.S., they tend to overestimate cardiac risk in
on-U.S. and minority populations (3,20,24,25). This is
ften correctable with recalibration for the event rate within
he population, reflecting a systematic error of the Framing-
am equation such that it is either overestimating or
nderestimating events by a constant factor (20,23,26–29).
lthough the predictive utility of the Framingham equa-
ions in CKD improve after recalibration for higher event
ates, with improvement particularly notable in women,
ecalibrated Framingham equations remained inadequate in
en with stage 3 to 4 CKD.
This manuscript dramatically expands on recent findings
y our group where we showed that adding a CKD term to
he Framingham equations identified additional at-risk
ndividuals but did not improve discrimination in a popu-
ation that included individuals both with and without
KD (30). Focusing only on individuals with CKD, we
xplored the relationship between specific traditional risk
actors and outcomes in individuals with CKD and found
hat, although many traditional risk factors remained im-
ortant in CKD, they carried different weight. While it is
ot entirely apparent why the Framingham instrument is
naccurate in CKD, the regression coefficients presented in
able 3 suggest several hypotheses. In men with CKD,
levated blood pressure and elevated total cholesterol do not
arry the same risk that is seen in the Framingham cohort;
urther, there appears to be no relationship between high-
ensity lipoprotein cholesterol and outcomes, and the im-
ort of diabetes appears greater. In women, cholesterol
gain has less of an effect while diabetes assumes more
mport and blood pressure has a marked “J”-shaped rela-
ionship. The Framingham equations, as currently designed,
nticipate that the relationship between risk factors like
levated cholesterol and elevated blood pressure with out-
omes will be linear when examined on a population scale.
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Figure 3 Cardiac and Mortality Event Rates
Actual 5- and 10-year composite outcomes (consisting of cardiac outcomes
and all-cause mortality) stratified by quintile of predicted Framingham risk.
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July 17, 2007:217–24 Framingham Prediction in Kidney Diseaseowever, in individuals with a chronic condition like CKD,
ower blood pressure and lower cholesterol may be identi-
ying individuals with greater infirmity; this is well described
n dialysis patients (31). Additionally, the mortality rate in
en with CKD is very high. These factors make develop-
ent of prediction models challenging as: 1) many risk
actors for mortality are also risk factors for cardiac events;
nd 2) in the most infirm individuals, risk factors and
utcomes may have an altered relationship. In women,
here the mortality rate is lower, this is less important.
hese altered, nonlinear relationships may reflect subclinical
VD; for example, the coexistence of diabetes and kidney
isease identifies individuals with severe enough diabetes to
evelop end-organ damage. Accordingly, similar findings
or the impact of diabetes on cardiac outcomes were
ppreciated in an assessment of the Framingham risk score
n kidney transplant recipients (32). Therefore, these find-
ngs may suggest that the dual presence of CKD and
raditional risk factors like diabetes and hypertension indi-
ates a greater duration or severity of these risk factors—this
ould not be accounted for in the Framingham risk score.
Similarly, recalibration failure in CKD may be explained
y the competing high mortality rate seen in this popula-
ion, as individuals who die are also those at highest risk for
oronary disease. In subjects with CKD, 10-year mortality
xceeded 35% in men and 20% in women, rates nearly 4
imes higher than those appreciated in the Framingham
erivation cohort. In the lowest 4 quintiles of Framingham
isk in men with CKD, observed events reliably exceed
redicted events; however, in the highest risk quintile,
redicted events far exceeded observed events. This paradox
s explained by the effects of mortality and is presented in
igure 3, where, after evaluating a composite outcome of
ardiac events and all-cause mortality, 5- and 10-year event
ates in men reliably increase as quintile of Framingham risk
ises. In women, where for any given age the mortality rate
s lower than seen in men, the competing risk presented by
ortality is less important and recalibration is more successful.
Our study has several limitations. Because most partici-
ants with kidney disease had estimated GFR above 40
l/min/1.73 m2, we cannot comment on the utility of
ramingham equations in more advanced disease. However,
t is notable that the vast majority of individuals in the U.S.
ith CKD and impaired kidney function, nearly 8 million
eople, fall into this GFR range. We do not have data on
icroalbuminuria, a component of kidney disease that
ndependently predicts CVD (4,33,34). Additionally, be-
ause of the limited size of the CKD population, we lack the
tatistical power to perform race-specific analyses.
Our study has several strengths. The pooled cohort
omprises a large population-based cohort with decreased
idney function and represents a diverse population with a
ide age range. Both ARIC and CHS, reflecting their
esign as community-based cardiovascular studies, have
horough cardiac and mortality event ascertainment. Addi-
ionally, we have detailed medical histories and data thatllow creation of a cohort of individuals with CKD without
nown prior coronary disease.
onclusions
lthough traditional risk factors are important predictors of
ardiac events in individuals with CKD, the Framingham
quations do not accurately weight these risk factors in
redicting coronary heart disease events in CKD. Much of
his failure is driven by competing events with death as well
s the significantly higher cardiac event rate in CKD
atients. While it is possible to somewhat improve coronary
eart disease prediction in individuals with CKD, particu-
arly in women, both by recalibrating the equations and by
ssigning different importance to traditional Framingham
isk factors, it is likely that future predictive equations with
dequate sample size for development and validation of a
redictive model in CKD will need to examine both cardiac
vents and mortality in this high risk population with the
oal of identifying shared modifiable risk factors for adverse
utcomes.
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ivision of Nephrology, Box #391, Tufts-New England Medical
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